Myeloproliferative Neoplasms News

A randomized phase 3 study of parsaclisib plus ruxolitinib for adults with myelofibrosis appeared unlikely to meet its primary endpoint and will be discontinued, according to the agents’ manufacturer.

Outpatient hematopoietic stem cell transplantation following targeted antibody-based conditioning appeared safe and feasible among older patients with acute myeloid leukemia or myelodysplastic syndrome, according to study results.

Imetelstat conferred a “highly statistically significant and clinically meaningful benefit” vs. placebo in enabling certain patients with myelodysplastic syndrome to achieve transfusion independence, according to the agent’s manufacturer.

NEW ORLEANS — A regimen containing post-transplant cyclophosphamide significantly lowered graft-versus-host disease risk among adults who underwent reduced-intensity allogeneic hematopoietic stem cell transplant, study results showed.

ASH recognized three Choosing Wisely champions and three guideline implementation champions at this year’s ASH Annual Meeting and Exposition.

The FDA announced several regulatory actions the past few weeks.

This year’s ASH Annual Meeting and Exposition spotlighted practice-changing research in malignant and benign hematology.

NEW ORLEANS — Patients with higher-risk myelodysplastic syndrome continue to experience suboptimal outcomes, according to study results presented at ASH Annual Meeting and Exposition.

Pelabresib plus ruxolitinib conferred benefit to Janus kinase inhibitor-naive patients with myelofibrosis, according to study results presented at ASH Annual Meeting and Exhibition.

NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, assistant professor at the Cleveland Clinic Taussig Cancer Institute, discusses updated results from the Momentum phase 3 study presented at the ASH Annual Meeting and Exposition.